Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wockhardt In Final Stages Of Talks To Sell German Operation To Lindo Pharm

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Financially troubled Indian drug maker Wockhardt is close to selling Esparma - its German operation - to Lindo Pharm, a privately held German company specializing in thyroid preparations and antibiotics

You may also be interested in...

With Large Biosimilars Opportunity In Sight, Multinational Companies Open Dialogue With India’s Wockhardt

MUMBAI - Adversities are throwing up unexpected opportunities for the debt-ridden Indian drug maker Wockhardt. While the company is being helped to tide over its unprecedented financial crisis of $600 million in debts by a group of large Indian banks, strategic opportunities in its biotech businesses have now come to surface

Unable To Manage Debts, India’s Wockhardt Calls For Financial Restructuring; Habil Khorakiwala Resigns As Managing Director

MUMBAI - After plunging into a veritable financial crisis due to high debt levels, India's pharmaceutical and biotechnology company Wockhardt has called for a financial debt restructuring through ICICI Bank

After Months Of Silence, Wockhardt Says It Has “Enough Business Bandwidth” To Ensure Payments Of FCCBs

MUMBAI - Drug major Wockhardt indicated that it has "enough bandwidth" in its business model to ensure that all its balance payments will be made in the stipulated time, in response to PharmAsia News queries on market speculation about its forthcoming payment of foreign currency convertible bonds of nearly $110 million. The bonds are scheduled to come up for redemption in September later this year




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts